High uric acid (UA) downregulates bone alkaline phosphatase (BALP) expression through inhibition of its promoter activity

Zhi-Qi Wu; Xiao-Ting Chen; Yan-Yan Xu; Ming-Jie Tian; Hai-Yan Chen; Guo-Ping Zhou; Hua-Guo Xu

doi:10.18632/oncotarget.21110

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

High uric acid (UA) downregulates bone alkaline phosphatase (BALP) expression through inhibition of its promoter activity

Zhi-Qi Wu, Xiao-Ting Chen, Yan-Yan Xu, Ming-Jie Tian, Hai-Yan Chen, Guo-Ping Zhou and Hua-Guo Xu _

PDF | HTML | How to cite

Oncotarget. 2017; 8:85670-85679. https://doi.org/10.18632/oncotarget.21110

Metrics: PDF 1916 views | HTML 2656 views | ?

Abstract

Zhi-Qi Wu1,*, Xiao-Ting Chen1,*, Yan-Yan Xu2,*, Ming-Jie Tian1, Hai-Yan Chen1, Guo-Ping Zhou2 and Hua-Guo Xu1

1Department of Laboratory Medicine, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China

2Department of Pediatrics, The First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province 210029, China

*These authors contributed equally to this work

Correspondence to:

Hua-Guo Xu, email: [email protected]

Keywords: bone alkaline phosphatase, uric acid, promoter, bone metastasis

Received: August 02, 2017 Accepted: September 03, 2017 Published: September 20, 2017

ABSTRACT

Bone metastases often occur in prostate cancers, lung cancers and breast cancers. Bone alkaline phosphatase (BALP) is one of the most commonly used serological markers for clinical evaluation of bone metabolism. Here, we reported that high concentrations of uric acid (UA) caused decrease of BALP levels and revealed that the effect of high concentrations of UA on the BALP expression was through inhibition of its promoter activity. Our results suggested physicians to think about serum UA status of patients with advanced cancer to avoid misdiagnosis when BALP was used to diagnose or assess the extent of bone metastases.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21110

Publication Alerts

Research Papers:

High uric acid (UA) downregulates bone alkaline phosphatase (BALP) expression through inhibition of its promoter activity

Abstract